Markets
Will hormone therapy for menopause be officially recommended over non-hormonal treatments by the Endocrine Society by September 2026?
Yes0%No0%
Loading...
About this market
This market resolves to Yes if the Endocrine Society publicly announces, by September 2026, that hormone therapy is recommended over non-hormonal treatments (including fezolinetant) for menopause based on official guidelines or recommendations. The announcement must clearly state preference and be available on the Endocrine Society's official communication channels.
Rules
- Market closes at 9/30/2026.
- Logic weighted resolution applies.
Given the current discussions around menopause treatments, I think it's unlikely the Endocrine Society will officially recommend hormone therapy over non-hormonal options by September 2026. Recent studies have shown that while hormone therapy can alleviate symptoms, non-hormonal treatments are gaining popularity due to safety concerns. The market seems to underestimate the weight of evidence against hormone therapy; the risks are still substantial, and women are increasingly looking for alternatives. That said, I can see why some traders might believe in a shift, given pressures from pharmaceutical companies to promote hormone treatments. Overall, I would lean towards a no here, considering the current data trends.
Rationale:The comment provides a well-reasoned perspective on the likelihood of hormone therapy being recommended over non-hormonal treatments, supported by references to recent studies and trends. The scores reflect a strong factual basis with minor uncertainties, a lack of logical fallacies, and high relevance to the market question. The weights prioritize fact-checking due to the reliance on current data trends, while still acknowledging the logical structure of the argument.
It seems unlikely that the Endocrine Society will officially recommend hormone therapy over non-hormonal treatments by September 2026. The ongoing debate around the risks and benefits of hormone therapy has not reached a consensus, and many guidelines aim for individualized treatment based on patient needs rather than a blanket recommendation. It feels premature to assume a shift in advice when the focus has increasingly been on safer alternatives and minimizing risks. The current market price might reflect some optimism, but I don't think it aligns with the complex realities of medical recommendations.
Rationale:The comment provides a well-reasoned perspective on the complexities surrounding hormone therapy recommendations, which is relevant to the market question. It accurately reflects the ongoing debate and the emphasis on individualized treatment, supporting a high score for relevance and a solid score for fact check. The logical structure is sound, with no fallacies detected, though there is a slight emotional appeal in expressing skepticism about the market's optimism. Weights were adjusted to reflect the importance of factual accuracy and logical coherence in this context.
Given the recent studies showing benefits of hormone therapy, I think the market is underestimating the likelihood of a recommendation by September 2026.
Rationale:The comment accurately references recent studies indicating benefits of hormone therapy, which supports the claim about the market's underestimation. It is logically sound and directly relevant to the market question, with a slight emotional appeal. The weights reflect the importance of factual accuracy and relevance in this context.
The odds seem too low for this recommendation to happen by September 2026. The Endocrine Society's previous guidelines have been cautious about hormone therapy, and existing data from the WHI study shows mixed results on risk benefits. I expect they might still favor non-hormonal options.
Rationale:The comment accurately references the Endocrine Society's cautious stance on hormone therapy and the mixed results from the WHI study, which supports a high Fact Check score. It directly addresses the market question regarding the recommendation timeline, ensuring high relevance. The argument is logically sound with no fallacies detected, though it does contain some emotional elements regarding expectations. The weights reflect the importance of factual accuracy and relevance in this context.
The current odds seem overly confident in a yes vote. Given the mixed findings from studies around hormone therapy risks and benefits, it feels like a 50-50 at best. The Endocrine Society has historically been cautious about pushing hormone treatments, so I wouldn't be surprised if they stick to non-hormonal approaches for a bit longer. I'd buy into the no side if the spreads improve.
Rationale:The comment accurately reflects the uncertainty surrounding hormone therapy for menopause, citing mixed findings and the Endocrine Society's cautious history. It logically assesses the market odds and expresses a personal investment strategy, which keeps it relevant. The weights reflect a balanced focus on factual accuracy and logical reasoning, with some emotional appeal regarding personal investment. Overall, the comment is well-reasoned and relevant to the market question.
The current price seems low considering the increasing evidence supporting the benefits of hormone therapy for menopausal symptoms; I expect a recommendation soon.
Rationale:The comment accurately reflects a positive outlook on hormone therapy based on increasing evidence, though it lacks specific references to that evidence, leading to a score of 80 for Fact Check. It is logically sound with no fallacies detected, hence a high score in that category. The comment is relevant to the market question but does not delve deeply into the specifics of the recommendation process, justifying a slightly lower score for Relevance. The emotional appeal is present but not overwhelming, leading to a balanced score in Logic/Emotion. The weights emphasize Fact Check due to the reliance on evidence, while No Fallacies and Relevance are also important but slightly less so.
I doubt the Endocrine Society will fully endorse hormone therapy over non-hormonal alternatives by September 2026. The historical hesitance surrounding hormone therapy and its risks makes me think they will continue to recommend a balanced approach.
Rationale:The comment presents a reasonable skepticism regarding the Endocrine Society's potential endorsement of hormone therapy, supported by historical context. While the claim about historical hesitance is accurate, it lacks specific evidence or data to strengthen the argument, leading to a slightly lower score in Fact Check. The comment is logically sound and relevant to the market question, with a balanced emotional appeal, justifying the weights assigned.
hormone therapy is already widely accepted as a go-to for menopause treatment in many circles, so saying the Endocrine Society won't recommend it by September seems off. I'd argue there's over 60% chance they'll back the current trend, especially since non-hormonal options have had mixed results. just saying, the price should probably reflect a higher likelihood.
Rationale:The comment presents a mostly accurate view of hormone therapy's acceptance, but lacks specific evidence to support the claim about the Endocrine Society's future recommendations, leading to a score of 75 for Fact Check. It logically argues the likelihood of a recommendation without major fallacies, hence a score of 85 for No Fallacies. The relevance to the market question is high, as it directly addresses the likelihood of the Endocrine Society's recommendations. The emotional appeal is present but balanced with logical reasoning, resulting in a score of 80 for Logic/Emotion. The weights reflect the importance of factual accuracy and logical coherence in this context.
i seriously doubt they'll make a switch that big by september, non-hormonal treatments have been the go-to for a while and a lot of docs are still skeptical about hormones.
Rationale:The comment expresses skepticism about the likelihood of a significant change in treatment recommendations by the Endocrine Society, which is a reasonable perspective given the current preference for non-hormonal treatments. The factual accuracy is mostly sound, but it lacks specific evidence to support the claims about doctors' skepticism. The comment is relevant to the market question and free from major logical fallacies, but it does contain some emotional appeal. The weights reflect a balanced focus on relevance and logical soundness while acknowledging the need for factual support.
the Endocrine Society has leaned towards non-hormonal treatments in the past, so I'm skeptical about the market's optimism for this move.
Rationale:The comment accurately reflects a historical trend of the Endocrine Society favoring non-hormonal treatments, which supports a skeptical view of the market's optimism. However, the claim lacks specific evidence or recent data to fully substantiate it, leading to a score of 70 for Fact Check. The comment is logically sound and relevant to the market question, but it does not provide a strong emotional appeal, resulting in a balanced score across the other criteria. The weights reflect the importance of factual accuracy and logical coherence in this context.